Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow the injection and tablet compare, evidence, practicalities and eligibility
You've been offered a choice nobody had a year ago
Picture this: your prescriber tells you there are now two licensed semaglutide options for weight management in the UK, the once-weekly injection you may already know as Wegovy, and a daily tablet approved by the MHRA in June 2026 as the first oral GLP-1 medicine for weight loss in the country. That choice didn't exist until recently, so it's reasonable to feel unsure which to ask for.
The injection delivers semaglutide subcutaneously (under the skin) giving reliably high bioavailability. In the STEP 1 trial published in the New England Journal of Medicine, 68 weeks of weekly 2.4 mg semaglutide produced around 15% average body-weight reduction. A higher 7.2 mg dose was subsequently approved by the MHRA in 2026, with trial data showing roughly 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide at its highest dose.
The oral tablet reaches the bloodstream differently. It relies on an absorption enhancer called SNAC, and it must be taken first thing in the morning on an empty stomach, swallowed whole with a small amount of plain water, then no food, drink or other oral medicine for at least 30 minutes. Get that routine wrong and absorption drops sharply. In the OASIS 4 phase-3 trial, the tablet produced around 13.6% average weight loss over 64 weeks, and roughly 16–17% among participants who stuck fully to the protocol. You can read more about how the tablet works if you want the fuller picture before your consultation.
The gap in average trial results is real but not enormous, and trials are not head-to-head. If you are weighing up whether oral semaglutide is as effective as injection, that depends on your biology, your adherence and how your prescriber titrates your dose. That's a clinical conversation, not a headline.
What the numbers actually show side by side
A clean comparison makes the evidence easier to hold in your head. The figures below are from published trial data; they are population averages, not guarantees for any individual.
| Factor | Wegovy injection (semaglutide) | Wegovy tablets (oral semaglutide) |
|---|---|---|
| Route | Once-weekly subcutaneous injection | Once-daily oral tablet |
| Average weight loss (trial) | ~15% at 2.4 mg (STEP 1, 68 wks); ~20.7% at 7.2 mg (72 wks) | ~13.6% overall; ~17% fully adherent (OASIS 4, 64 wks) |
| UK licence for weight loss | Yes (BMI ≥30, or ≥27 with a weight-related condition | Yes) BMI ≥30, or ≥27 with a weight-related condition |
| MHRA approval date (weight management) | Ongoing; 7.2 mg single-dose pen approved April 2026 | 11 June 2026 (first oral GLP-1 for weight loss in UK) |
| Storage | Refrigerated (2–8°C); limited room-temperature window per leaflet | Room temperature, no fridge needed |
| NHS availability | Via specialist weight management services (NICE TA875) | No NICE appraisal yet; private prescription only at launch |
On storage: one thing patients mention is the fridge. The injection pen sits in there alongside your food, which is a daily visual reminder but also means planning for travel. The tablet travels in your bag or bedside drawer without refrigeration, a practical difference worth naming, not overstating. You can explore the full oral vs injection breakdown for more detail on each route's logistics.
Neither Ozempic nor Rybelsus features in this comparison. Ozempic is semaglutide licensed for type 2 diabetes, not weight management. Rybelsus is also oral semaglutide, but again only licensed for diabetes, in different strengths to the weight-loss tablet. If you've seen those names mentioned in the context of weight loss, the explainer on semaglutide forms and licences clarifies exactly where the lines are drawn. The NHS medicines page for semaglutide covers the licensed uses too.
Routine fit and side effects: the daily reality
The injection is weekly. Once it's done, you don't think about it for seven days. Many people find that simplicity valuable. The injection site rotates between the abdomen, thigh and upper arm; good technique matters, and your prescriber can walk you through it at consultation.
The tablet demands more from your morning. Empty stomach, specific timing, then a half-hour wait before coffee. For some people that's straightforward, tablets fit the way they already think about medicines. For others, the pre-breakfast window is genuinely difficult to protect.
Side effects share a family resemblance across both forms because the active molecule is the same: nausea, loose stools, constipation, reflux and fatigue are the most commonly reported, and they tend to be worst in the early weeks or after a dose increase, then settle. The oral route showed higher rates of gastrointestinal effects in the OASIS 4 trial, 74% of tablet users vs 42% in the placebo group reported GI events, most of them mild to moderate. If you want to understand how the two routes compare on tolerability, that page goes deeper.
Pancreatitis is a known but uncommon risk with GLP-1 medicines. The MHRA highlighted it in a Drug Safety Update in January 2026: severe stomach pain that extends towards the back, with or without vomiting, warrants urgent medical attention. Both forms carry this note. Report any unexpected side effects through the MHRA Yellow Card scheme.
Eligibility for either form sits with your prescriber. A BMI of 30 or above, or 27 or above alongside a weight-related condition, is the licensed starting point, but BMI alone is never the whole picture. A real clinician reads your answers; a named prescriber, not an algorithm, makes the call. If you'd like to read a detailed comparison of semaglutide tablets vs injection before you decide, that's worth reading alongside this page. Then, when you're ready, speak to our prescribers and they'll work through which option fits your situation.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.